Telo Genomics Corp(TDSGF)
USD --+0.00%
Reward40Moderate
Risk42Moderate
📊75%Data
TDSGF
+0.0 · +0.00%
USD · OTCQB
Telo Genomics Corp | Healthcare
Capital Destroyer
Market Cap:3.85M
ℹ️
Reward Rating
40
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
42
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on TDSGF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Telo Genomics Corp?

, a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada.

TDSGF · Verdict

Moderate reward · moderate risk

TDSGF stands out on volatility and balance sheet, but watch the cash flow signal.

Based on 88% data coverage

TDSGF · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Balance sheet88/100

    Current ratio 2.25

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -52001% return on equity

  • Growth41/100

    Earnings +8.8% CAGR

Model-based scoring. For information only — not financial advice.

What is Telo Genomics Corp?

, a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 3.85M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap3.85M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.09
52 Week Low0.03
Last AnnualJune
IPO DateN/A
IncorporatedUSA
Shares Outstanding100M
No. of EmployeesN/A
IndustryDiagnostics & Research
ExchangeOTCQB
Beta0.035
CurrencyUSD · Reports in CAD